Nova Biomedical: StatStrip Ketone Strips Recall Causes UK Supply Disruption

• Nova Biomedical has initiated a recall of specific StatStrip ketone test strip lots due to repeated quality-control failures.
• The recall and paused distribution are expected to cause significant disruption to blood ketone testing in the UK, with replacement stock not anticipated for four weeks.
• Blood ketone testing is vital for diagnosing and monitoring diabetic ketoacidosis (DKA), a potentially life-threatening condition.
• Loss of timely testing capacity could lead to delayed DKA recognition, treatment, and monitoring, increasing risks of severe patient harm or death.
• NICE guidelines emphasize near-patient blood ketone measurement for suspected DKA, especially in children and young people.

Such delays can result in severe clinical deterioration, critical illness, permanent harm, or even death, highlighting the severe patient safety implications.

Nova Biomedical has initiated a recall for specific lots of its StatStrip ketone test strips due to identified quality issues. These issues stem from repeated quality-control (QC) failures, leading the manufacturer to advise against the use of the affected lots. In addition to the recall, Nova Biomedical has halted the distribution of these problematic batches and instructed that any further lots exhibiting QC failures should also be withdrawn from circulation. This action is documented under medical device alert DSI/2026/013.

The combined effect of this Nova Biomedical StatStrip ketone strips recall, paused distribution, and potential further withdrawals is expected to progressively reduce the availability of these critical test strips. This situation poses a significant risk of disruption to blood ketone point-of-care testing across the UK. Compounding the issue, Nova Biomedical has indicated that replacement stock will not be available in the UK for approximately four weeks, exacerbating the potential for a severe UK ketone test strip supply disruption during this period.

Blood ketone testing serves as an essential diagnostic and monitoring tool for patients at risk of, or already experiencing, diabetic ketoacidosis (DKA). This potentially life-threatening condition requires prompt and accurate assessment, making reliable ketone testing indispensable. The NHS guidelines specify that blood ketone concentrations exceeding 3 mmol/L may indicate DKA, necessitating immediate emergency assessment.

The utility of blood ketone testing spans a wide array of healthcare environments, including emergency departments, acute inpatient services, and pediatric care. It is also routinely employed by ambulance and paramedic services, in community hospitals, during urgent community responses, within virtual wards, and in hospital-at-home services, as well as in primary care and by district/community nursing teams. The widespread application underscores the critical importance of maintaining consistent supply and quality for diabetic ketoacidosis DKA testing impact.

National Institute for Health and Care Excellence (NICE) guidelines integrate blood ketone measurement into both the diagnostic and monitoring pathways for DKA. Specifically, for children and young people where DKA is suspected, NICE recommends the use of a near-patient method for measuring blood ketones. Should such a method be unavailable, NICE advises immediate transfer to a hospital equipped with acute pediatric facilities.

The most significant clinical risk associated with the loss of timely blood ketone testing arises when a patient is acutely unwell, DKA is suspected or actively being treated, and no alternative validated method for obtaining a clinically appropriate ketone result is immediately accessible. The MHRA StatStrip quality control failures directly contribute to this risk. A reduction in testing capacity could lead to delays in recognizing or assessing DKA, postponing escalation or hospital transfers, hindering timely treatment decisions, or impairing the effective monitoring of treatment response. Such delays can result in severe clinical deterioration, critical illness, permanent harm, or even death, highlighting the severe patient safety implications. The Department of Health and Social Care is expected to issue further clinical guidance to address these concerns.

Compliance officers in healthcare settings must immediately verify the withdrawal of affected Nova Biomedical StatStrip ketone test strip lots and implement contingency plans for blood ketone testing to mitigate patient safety risks, particularly concerning delayed DKA diagnosis and treatment, which could lead to increased liability exposure.

Source: Original reporting via GOV.UK medical device alert